CGMs are gonna rain down! Yup, healthcare tech companies are clamoring to develop new systems to appeal to a broad spectrum of potential users. According to an article by Craig Idlebrook for DiabetesMine.com, 19 February 2020, “we’ve identified at least three dozen efforts to develop new CGMs and novel meters — some of them aiming for the holy grail of noninvasive glucose monitoring: not needing to pierce the skin.”
Thank you, @DanaLewis for the fabulous cartoon!
This is just a summary list … details in the link below to the full article.
- Alertg: noninvasive CGM system ANICGM using miniaturized MRI-like technology on wristband.
- Know Labs: UBAND uses radio waves to measure glucose levels.
- LifePlus: LifeLeaf detects blood glucose levels, blood pressure, heart rate, sleep apnea, etc.
- PK Vitality: Device is said to sample bodily fluids through microneedles under the watch.
- Prediktor Medical: a noninvasive armband CGM called BioMK.
Traditional Wearable Sensors
- i-SENS: Asian-based fingerstick meter manufacturer plans to roll out a CGM in 2021.
- Pacific Diabetes Technologies: Oregon CGM with sensor that also has a port for insulin delivery. The company received JDRF funding and hopes to seek FDA review in roughly 2023.
- WaveForm Technologies: Cascade CGM system with thin 14-day sensor and rechargeable transmitter, sends real-time readings via BT to app. Doesn’t expect to launch until 2021.
- POCTech: CT-100M clinical trial data shows it may be the most accurate on the market.
- Roche Diabetes Care:
- Medtrum: A6 TouchCare System, a tubeless semiautomated insulin delivery system with CGM.
- SanaVita Medical: SanaVita OneTouch Real Time CGMS clinical trial in early 2020.
- Glucovation: SugarSenz, a highly accurate, low-cost wearable CGM.
- Infinovo: Glunovo i3 CGM with 14 day sensor. CGM has been granted a CE mark in 2019.
- GlucoRx: Needle-free insertion, reusable sensor applicators, and brief warmup time.
Implantable CGM sensors
- Integrated Medical Sensors: Irvine, California start up, from CalTech implantable CGM the size of a sesame seed. It will last under the skin for as long as 6 to 9 months.
- Profusa: Lumee Oxygen, 10th of an inch long and would be injected under the skin, where it could work for up to 2 years. Funding: U.S. Army, DARPA and National Institutes of Health.
- Metronom Health: Belgium-based hair-thick sensor that can be worn under the skin for 14 days, communicate to apps via small, disposable transmitter.
- GluSense: Israeli implantable CGM using encapsulated fluorescent glucose sensor implanted for up to a year. In 2017, received $2 million in JDRF funding.
- GlySens: San Diego–based an implantable CGM (ICGM) to be worn under the skin for a year or longer. Includes transmitter worn externally.
- PercuSense: Southern California–based implantable CGM, doesn’t require calibration and utilizes an electromagnetic signal. Partners:Diabeloop, SFC Fluidics and JDRF funded.
- Biolinq: San Diego nickel-sized, needle-free CGM with rechargeable battery and built-in transmitter to monitor glucose trends and other biomarkers. Recently received $4.75 million in funding from the JDRF’s T1D Fund.
- Nemaura Medical: U.K. SugarBEAT CGM, patch sensor uses mild electrical current to draw small amounts of glucose from under the skin. Cost at one-fifth of other CGMs but not as accurate. Launching internationally, submitted to FDA in July 2019.
- GraphWear Technologies: San Francisco continuous patch sensor to detect biomarkers, including glucose, through sweat.
- Medtronic: Filed for patent in September 2018 for glucose monitoring patch that would change colors based on glucose readings taken by sweat.
- Sano: San Francisco patch biosensor that can deliver readings for vital stats that include glucose levels. Fitbit invested $6 million into the idea in 2018.
- University of California, San Diego: Temporary tattoo with integrated thin and flexible sensors can provide accurate glucose readings from sweat. A pilot study concluded in June 2019.
- AnnNIGM: Russian meter that can be worn as an ear clip.
- Integrity Applications: Device clips to the ear, uses a combination of ultrasonic, electromagnetic, and thermal technologies to measure glucose levels.
- EasyGlucose: UCLA student-led monitor by imaging the retina. Special lens affixed to smartphone camera to monitor changes in the retina. Won Microsoft’s Imagine Cup in 2018.
- NovioSense: Dutch CGM device that rests on lower eyelid to measure glucose through tears.
- CNOGA Medical: Israeli CGM (CoG) uses fingerprick readings for initial calibration and light-emitting diodes for noninvasive readings.
- DiaMonTech: German noninvasive CGM system using infrared light beam to count glucose molecules under the skin. Hopes to launch in 2020.
- Indigo Diabetes: Belgian noninvasive CGM to use photonic light to measure glucose levels. The company was featured at the J.P. Morgan 2020 Healthcare Conference.
- MTI: U.K. GlucoWise, noninvasive glucose monitor using radio waves to measure glucose levels.
- The University of Waterloo: Proof-of-concept system using Google radar technology.
- The University of Bath: U.K. thin, graphene-based glucose sensor, using miniature sensors utilizing a small electric current to draw glucose out from the interstitial fluid.
- Echo Therapeutics: Noninvasive CGM (NextGen) to track glucose levels through the skin.
Read all the details: 39 Potential New Continuous Glucose Monitors for Diabetes
More and MORE Type 1 diabetes and IT’S COSTLY … YIKES!!! Make it stop!
Type 1 Diabetes Up 30% Since 2017, According to CDC Report was reported by JDRF which issued a statement based on two new reports issued by the Centers for Disease Control and Prevention, which estimates a nearly 30% increase in the number of T1D cases in the United States in the last two years, with youth cases growing most sharply among minority groups.
The CDC’s 2020 National Diabetes Statistics Report cites that in the United States, T1D diagnoses included 1.4 million adults, 20 years and older, and 187,000 children younger than 20. That totals nearly 1.6 million Americans with T1D – up from 1.25 million people – or nearly 30% from 2017.
Is Type 1 Diabetes Much More Common than We Think? was reported by Ross Wollen for ASweetLife.org, February 2020.
In the United States, about 30 million people are said to have diabetes. Of those, about 1 million are diagnosed with Type 1, and the other 29 million are diagnosed with (or suspected of having) Type 2. But is that ratio accurate? Or does it reflect a misunderstanding of the nature of Type 1 diabetes?
Dr. David Leslie, Professor of Diabetes and Immunology at London University’s Blizard Institute, thinks the real numbers “will definitely be different: The number of people with Type 1 is probably much higher than we’ve accounted for. That 29 million – something like 2 million of them may have undiagnosed Type 1.”
A recent study from the University of Exeter last year showed that “38% of patients with Type 1 diabetes occurring after age 30 were initially treated as Type 2 diabetes,” and, even more strikingly, that “half of those misdiagnosed were still diagnosed as Type 2 diabetes 13 years later.”
The paper, published in the journal BMC Medicine, discusses surprising amount of variance in C-peptide persistence in people with Type 1 diabetes. While it was once thought that everyone with T1D rapidly declined towards zero insulin production, what we now know is that C-peptide persistence varies widely across a spectrum. Most people with T1D retain at least some ability to produce insulin, even after many years, and many retain so much that they haven’t even been identified as having T1D.
New JDRF-Funded Study finds Lifetime T1D Management Costs a Collective $813 Billion was published in Advocacy, Life with T1D, Research News, JDRF, 24 February 2020.
According to a new study published in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), people who live with Type 1 Diabetes (T1D) in the United States right now, as well as those who will develop the disease over the next 10 years, will pay a collective $813 billion over their lifetimes in medical costs and in lost income and productivity costs, as compared to a similar group that does not have T1D.
On an individual level, this translates to nearly $500,000 per person over the course of a lifetime.
The study, “Estimated Lifetime Economic Burden of Type 1 Diabetes,” was funded by JDRF and The Leona M. and Harry B. Helmsley Charitable Trust.
Additional findings point to a 9-year life expectancy difference between those with and without T1D, as well as a concentration of T1D-associated costs being incurred within the first 50 years of one’s life.